In a kidney‑transplant recipient who underwent radical prostatectomy for Gleason 3+4 (grade group 2) pT2 prostate cancer with negative margins, with postoperative PSA ≤0.15 ng/mL for two years and stable PSA <0.2 ng/mL for the past 15 months, a PSA doubling time of 7 months and a Decipher genomic classifier score of 0.53, should we continue active surveillance or proceed with salvage intervention?

Surveillance is Appropriate in This Clinical Scenario

In a kidney-transplant recipient with Gleason 3+4 (Grade Group 2) pT2 prostate cancer, negative surgical margins, stable PSA <0.2 ng/mL for 15 months, and a Decipher score of 0.53, continued surveillance is warranted rather than immediate salvage intervention. 1

Rationale for Surveillance

Biochemical Recurrence Has Not Been Confirmed

• The AUA defines biochemical recurrence (BCR) after radical prostatectomy as two consecutive PSA measurements ≥0.2 ng/mL. 2, 1
• Your patient has maintained PSA <0.2 ng/mL for the past 15 months, which does not meet the BCR definition. 2, 1
• Approximately 8.8% of men exhibit detectable but stable PSA for ≥10 years without clinical progression. 1
• Salvage radiotherapy should only be initiated after BCR is confirmed; treating before this threshold provides no proven benefit and exposes patients to unnecessary toxicity. 1

PSA Doubling Time Indicates Low Risk

• A PSADT of 7 months, while relatively short, must be interpreted in the context of stable PSA values below the BCR threshold. 2, 1
• PSADT ≥15 months is associated with low risk of prostate-cancer-specific mortality over 10 years, but PSADT calculation is most meaningful when BCR is confirmed. 1, 3
• The current 15-month stability period suggests the PSA trajectory may not be as aggressive as the earlier 7-month doubling time implied. 1

Favorable Pathologic Features

• pT2 disease with negative surgical margins confers significantly lower recurrence risk compared to pT3 disease or positive margins. 1, 4
• Gleason 3+4 (Grade Group 2) without seminal vesicle invasion or extensive extraprostatic extension carries a favorable prognosis. 1
• The absence of adverse pathology (no seminal vesicle invasion, no positive margins) substantially diminishes the absolute benefit of immediate intervention. 2, 1

Decipher Score Interpretation

• The Decipher genomic classifier (score 0.53) should be interpreted in the context of clinical and pathologic factors rather than in isolation. 1
• Routine use of Decipher to select between adjuvant and salvage radiotherapy is not recommended in the absence of prospective trial evidence. 1
• With favorable pathologic features (pT2, negative margins) and stable PSA, the Decipher score alone does not override the lack of confirmed BCR. 1

Surveillance Protocol

PSA Monitoring Strategy

• Measure PSA every 3 months to verify stability and detect any upward trend promptly. 1, 3
• Use the same PSA assay platform throughout follow-up to avoid inter-method variability of approximately ±25%. 3
• If PSA begins to rise consistently, recalculate PSADT; a PSADT <15 months with rising PSA warrants closer monitoring. 1, 3

Clinical Examination

• Perform digital rectal examination (DRE) at each follow-up visit to assess for palpable local recurrence. 2, 1

Imaging Considerations

• Bone scintigraphy is not recommended when PSA is <10 ng/mL due to very low diagnostic yield. 2, 1, 3
• If BCR is confirmed (two consecutive PSA ≥0.2 ng/mL), consider PSMA-PET/CT to localize disease and guide salvage therapy decisions. 2, 1, 3

Triggers for Salvage Radiotherapy

Initiate salvage radiotherapy only when:

1. Two consecutive PSA measurements ≥0.2 ng/mL (meeting BCR definition). 2, 1
2. PSA reaches 0.5 ng/mL (optimal threshold for maximal salvage radiotherapy efficacy). 1
3. Consistent PSA rise with PSADT <15 months after BCR is confirmed, indicating more aggressive disease biology. 1

Timing of Salvage Radiotherapy

• When BCR is confirmed, salvage radiotherapy is most effective when PSA is ≤0.5 ng/mL. 1
• Five-year biochemical failure rates are 26.6% for PSA <0.2 ng/mL versus 57% for PSA 1.0–2.0 ng/mL. 1
• Delaying salvage radiotherapy beyond PSA 0.5 ng/mL significantly worsens oncologic outcomes. 1

Transplant-Specific Considerations

Prostate Cancer in Kidney-Transplant Recipients

• Kidney-transplant recipients have a ~7-fold higher incidence of prostate cancer (1,126 vs 160 per 100,000) and present more frequently with advanced disease (36% T3/T4, 19% metastatic). 3, 5
• Despite higher incidence and stage at presentation, cancer-specific survival and overall survival after treatment are comparable to non-transplant patients. 2, 5, 6
• Radical prostatectomy in transplant recipients yields cancer-specific and overall survival of 96.8% each. 1, 5

Immunosuppression Monitoring

• Although immunosuppression does not appear to significantly alter prostate cancer natural history, graft function must be monitored throughout cancer treatment. 2, 1, 5
• Combined azathioprine + calcineurin-inhibitor immunosuppression is linked to higher-stage disease versus calcineurin-inhibitor-only regimens. 1

Common Pitfalls to Avoid

Premature Intervention

• Do not initiate salvage therapy before confirming BCR (i.e., before two consecutive PSA ≥0.2 ng/mL). 2, 1
• Treating before BCR is confirmed exposes patients to unnecessary genitourinary toxicity without proven benefit. 1
• Acute GU toxicity (Grade 1-2) occurs in 3%–82% of salvage-radiotherapy patients; Grade 3-4 GU toxicity occurs in 0%–6%. 1
• Urethral strictures develop in 17.8% of patients receiving adjuvant radiotherapy versus 9.5% with observation alone. 1

Excessive Delay Once BCR Is Confirmed

• Once BCR is confirmed, avoid delaying salvage radiotherapy beyond PSA 0.5 ng/mL, as this markedly reduces biochemical control rates and increases cancer-specific mortality. 1

Neglecting PSA Kinetics

• A solitary elevated PSA may reflect assay error; trend analysis and PSADT calculation are essential. 2, 1, 3
• Repeat PSA testing in 3 months is advised to confirm true trends and exclude laboratory variation or benign residual tissue. 1

Misinterpreting Decipher Scores

• Decipher scores should not be used in isolation to trigger salvage therapy in the absence of confirmed BCR. 1
• Clinical and pathologic factors (stage, margins, Gleason score, PSA kinetics) remain the primary drivers of management decisions. 1